Gabapentin - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:55:56Z

Switch SMW query from broadtable to table format for better layout with TOC

← Older revision		Revision as of 21:55, 20 March 2026
Line 79:		Line 79:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

2026-03-20T17:25:20Z

Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

← Older revision		Revision as of 17:25, 20 March 2026
Line 81:		Line 81:
	\|format=broadtable		\|format=broadtable
	\|headers=plain		\|headers=plain
	\|~~link~~=~~subject~~		\|mainlabel=-
	\|sort=Has Indication		\|sort=Has Indication
	\|limit=50		\|limit=50

Danbot: Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

2026-03-20T16:43:30Z

Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

@@ Line 68: / Line 68: @@
 *Excretion: Renal
 *Mechanism of Action: GABA analogue, but has no effect on GABA binding, uptake or degradation; mech for analgesic and anticonvulsant activity unknown
 ==See Also==

Elcatracho: /* See Also */

2021-03-08T04:08:23Z

ClaireLewis: /* References */

2019-09-22T20:05:51Z

References

← Older revision		Revision as of 20:05, 22 September 2019
Line 75:		Line 75:

	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			[[Category:Neurology]]

ELEE1987: /* Serious */

2017-10-13T15:09:11Z

Serious

← Older revision		Revision as of 15:09, 13 October 2017
Line 54:		Line 54:
	==Adverse Reactions==		==Adverse Reactions==
	===Serious===		===Serious===
	*~~none~~		*Depression/suicidality
			* SJS
			* anaphylaxis
			* angioedema

	===Common===		===Common===
	*>10% ataxia, dizziness, fatigue, somnolence		*>10% ataxia, dizziness, fatigue, somnolence

Mholtz: Text replacement - "-->" to "→"

2017-02-08T22:48:34Z

Text replacement - "-->" to "→"

← Older revision		Revision as of 22:48, 8 February 2017
Line 21:		Line 21:
	===Neuropathic Pain===		===Neuropathic Pain===
	*600mg PO load in ED		*600mg PO load in ED
	*Discharge with 300mg ~~-->~~ 900mg per day divided tid (as in post-herpetic neuralgia regimen)		*Discharge with 300mg → 900mg per day divided tid (as in post-herpetic neuralgia regimen)
	*Discharge with pain specialist follow-up		*Discharge with pain specialist follow-up
	*Max dosage 3600mg if patient already on gabapentin		*Max dosage 3600mg if patient already on gabapentin

Neil.m.young: Text replacement - "0 mg" to "0mg"

2016-07-18T21:46:26Z

Text replacement - "0 mg" to "0mg"

← Older revision		Revision as of 21:46, 18 July 2016
Line 7:		Line 7:
	===Partial [[Seizures]]===		===Partial [[Seizures]]===
	*Adjunctive therapy for partial seizures with or without secondary generalization		*Adjunctive therapy for partial seizures with or without secondary generalization
	*Initial: ~~300 mg~~ PO q8hr		*Initial: 300mg PO q8hr
	*May increase up to ~~600 mg~~ PO q8hr<br />		*May increase up to 600mg PO q8hr<br />
	===Post herpetic neuralgia===		===Post herpetic neuralgia===
	*Day 1: ~~300 mg~~ PO qDay		*Day 1: 300mg PO qDay
	*Day 2: ~~300 mg~~ PO q12hr		*Day 2: 300mg PO q12hr
	*Day 3: ~~300 mg~~ PO q8hr<br />		*Day 3: 300mg PO q8hr<br />
	===Muscle Cramps (Off-label)===		===Muscle Cramps (Off-label)===
	*100-~~300 mg~~ PO qHS; may titrate to 300-~~400 mg~~ q8hr PRN		*100-300mg PO qHS; may titrate to 300-400mg q8hr PRN
	===Anxiety (Off-label)===		===Anxiety (Off-label)===
	*300mg PO qHS initially, THEN ~~300 mg~~ PO q8h; may further increase as tolerated<br />		*300mg PO qHS initially, THEN 300mg PO q8h; may further increase as tolerated<br />
	===Diabetic Neuropthy (Off-label)===		===Diabetic Neuropthy (Off-label)===
	*~~900 mg~~/day PO initially; may increase gradually q3Days to 1800-~~3600 mg~~/day		*900mg/day PO initially; may increase gradually q3Days to 1800-3600mg/day
	===Neuropathic Pain===		===Neuropathic Pain===
	*~~600 mg~~ PO load in ED		*600mg PO load in ED
	*Discharge with ~~300 mg~~ --> ~~900 mg~~ per day divided tid (as in post-herpetic neuralgia regimen)		*Discharge with 300mg --> 900mg per day divided tid (as in post-herpetic neuralgia regimen)
	*Discharge with pain specialist follow-up		*Discharge with pain specialist follow-up
	*Max dosage ~~3600 mg~~ if patient already on gabapentin		*Max dosage 3600mg if patient already on gabapentin
	*Taper dose > 7 days to discontinue<ref>Epocrates. Gabapentin Monograph. https://online.epocrates.com/u/10a1022</ref>		*Taper dose > 7 days to discontinue<ref>Epocrates. Gabapentin Monograph. https://online.epocrates.com/u/10a1022</ref>

Line 31:		Line 31:
	*<3 years: Safety and efficacy not established		*<3 years: Safety and efficacy not established
	*3-12 years (initial dose): 10-15mg/kg/day PO divided q8hr initially; titrate up in 3d to effective maintenance dose		*3-12 years (initial dose): 10-15mg/kg/day PO divided q8hr initially; titrate up in 3d to effective maintenance dose
	*3-4 years (maintenance): ~~40 mg~~/kg/day PO divided q8hr		*3-4 years (maintenance): 40mg/kg/day PO divided q8hr
	*5-12 years (maintenance): 25-35mg/kg/day PO divided q8hr		*5-12 years (maintenance): 25-35mg/kg/day PO divided q8hr
	*>12 years (initial dose): 300mg PO q8h; may increase up to ~~600 mg~~ PO q8h		*>12 years (initial dose): 300mg PO q8h; may increase up to 600mg PO q8h

	==Special Populations==		==Special Populations==
Line 39:		Line 39:
	*Lactation: Enters breast milk; use with caution		*Lactation: Enters breast milk; use with caution
	*Renal Dosing		*Renal Dosing
	: CrCl>60 mL/min: 300-~~1200 mg~~ PO TID		: CrCl>60 mL/min: 300-1200mg PO TID
	: CrCl 30-60 mL/min: 200-~~700 mg~~ q12hr		: CrCl 30-60 mL/min: 200-700mg q12hr
	: CrCl 15-29 mL/min: 200-~~700 mg~~ qDay		: CrCl 15-29 mL/min: 200-700mg qDay
	: CrCl<15 mL/min: 100-~~300 mg~~ qDay		: CrCl<15 mL/min: 100-300mg qDay
	: HD: 125-~~350 mg~~ posthemodialysis after each 4h dialysis interval		: HD: 125-350mg posthemodialysis after each 4h dialysis interval

	*Hepatic Dosing		*Hepatic Dosing

Neil.m.young: Text replacement - "5 mg" to "5mg"

2016-07-18T21:22:17Z

Text replacement - "5 mg" to "5mg"

← Older revision		Revision as of 21:22, 18 July 2016
Line 32:		Line 32:
	*3-12 years (initial dose): 10-15mg/kg/day PO divided q8hr initially; titrate up in 3d to effective maintenance dose		*3-12 years (initial dose): 10-15mg/kg/day PO divided q8hr initially; titrate up in 3d to effective maintenance dose
	*3-4 years (maintenance): 40 mg/kg/day PO divided q8hr		*3-4 years (maintenance): 40 mg/kg/day PO divided q8hr
	*5-12 years (maintenance): 25-~~35 mg~~/kg/day PO divided q8hr		*5-12 years (maintenance): 25-35mg/kg/day PO divided q8hr
	*>12 years (initial dose): 300mg PO q8h; may increase up to 600 mg PO q8h		*>12 years (initial dose): 300mg PO q8h; may increase up to 600 mg PO q8h

ClaireLewis: /* Neuropathic Pain */

2016-07-14T00:35:54Z

Neuropathic Pain

← Older revision		Revision as of 00:35, 14 July 2016
Line 21:		Line 21:
	===Neuropathic Pain===		===Neuropathic Pain===
	*600 mg PO load in ED		*600 mg PO load in ED
	*~~D/c~~ with 300 mg --> 900 mg per day divided tid (as in post-herpetic neuralgia regimen)		*Discharge with 300 mg --> 900 mg per day divided tid (as in post-herpetic neuralgia regimen)
	*~~D/c~~ with pain specialist follow-up		*Discharge with pain specialist follow-up
	*Max dosage 3600 mg if patient already on gabapentin		*Max dosage 3600 mg if patient already on gabapentin
	*Taper dose > 7 days to discontinue<ref>Epocrates. Gabapentin Monograph. https://online.epocrates.com/u/10a1022</ref>		*Taper dose > 7 days to discontinue<ref>Epocrates. Gabapentin Monograph. https://online.epocrates.com/u/10a1022</ref>

← Older revision		Revision as of 04:08, 8 March 2021
Line 70:		Line 70:

	==See Also==		==See Also==
			*[[Seizure]]
			*[[Anticonvulsants]]
			*[[Anticonvulsant levels and reloading]]
			*[[Neuropathy]]

	==References==		==References==